3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Recurrence
2
Small Cell Lung Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
6
Paclitaxel
5
Taxes
3
Docetaxel
3
Cisplatin
3
Gemcitabine
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Bevacizumab
2
talimogene laherparepvec
1
saracatinib
1
romidepsin
1
rilotumumab
1
ganitumab
1
Zoledronic Acid
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Therapeutics
1
Talc
1
Surveys and Questionnaires
1
Spectrum Analysis
1
Sodium Chloride
1
Pemetrexed
1
Nivolumab
1
Metformin
1
Magnetic Resonance Spectroscopy
1
Immunohistochemistry
1
Imatinib Mesylate
1
Gefitinib
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pleural Effusion, Malignant
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts